BRANDO, Chiara
 Distribuzione geografica
Continente #
NA - Nord America 1.800
EU - Europa 1.390
AS - Asia 1.224
SA - Sud America 228
AF - Africa 43
Continente sconosciuto - Info sul continente non disponibili 3
OC - Oceania 2
Totale 4.690
Nazione #
US - Stati Uniti d'America 1.750
SG - Singapore 530
RU - Federazione Russa 526
IT - Italia 355
CN - Cina 243
BR - Brasile 192
HK - Hong Kong 140
VN - Vietnam 123
DE - Germania 118
PL - Polonia 76
FR - Francia 73
GB - Regno Unito 69
FI - Finlandia 66
IN - India 36
JP - Giappone 30
CA - Canada 27
NL - Olanda 21
BD - Bangladesh 20
KR - Corea 18
IQ - Iraq 16
MX - Messico 14
IE - Irlanda 13
ZA - Sudafrica 11
SE - Svezia 10
AT - Austria 9
ES - Italia 9
RO - Romania 9
TR - Turchia 9
UA - Ucraina 9
NP - Nepal 7
PK - Pakistan 7
EC - Ecuador 6
ID - Indonesia 6
KE - Kenya 6
MA - Marocco 6
AE - Emirati Arabi Uniti 5
AR - Argentina 5
AZ - Azerbaigian 5
CO - Colombia 5
EG - Egitto 5
LT - Lituania 5
UY - Uruguay 5
BE - Belgio 4
IR - Iran 4
KZ - Kazakistan 4
MY - Malesia 4
PE - Perù 4
PH - Filippine 4
UZ - Uzbekistan 4
BO - Bolivia 3
CI - Costa d'Avorio 3
CL - Cile 3
DZ - Algeria 3
TN - Tunisia 3
VE - Venezuela 3
XK - ???statistics.table.value.countryCode.XK??? 3
AU - Australia 2
CH - Svizzera 2
CZ - Repubblica Ceca 2
DK - Danimarca 2
ET - Etiopia 2
GR - Grecia 2
MM - Myanmar 2
PA - Panama 2
PS - Palestinian Territory 2
PT - Portogallo 2
PY - Paraguay 2
TT - Trinidad e Tobago 2
AL - Albania 1
AM - Armenia 1
AO - Angola 1
BA - Bosnia-Erzegovina 1
BG - Bulgaria 1
CR - Costa Rica 1
DJ - Gibuti 1
DO - Repubblica Dominicana 1
EE - Estonia 1
GE - Georgia 1
GH - Ghana 1
GT - Guatemala 1
HU - Ungheria 1
JO - Giordania 1
LA - Repubblica Popolare Democratica del Laos 1
LV - Lettonia 1
MD - Moldavia 1
NG - Nigeria 1
RS - Serbia 1
SV - El Salvador 1
TH - Thailandia 1
VC - Saint Vincent e Grenadine 1
Totale 4.690
Città #
Ashburn 383
Singapore 318
San Jose 142
Chandler 132
Hong Kong 124
Moscow 104
Rome 86
Palermo 82
Fairfield 71
Zgierz 64
Los Angeles 63
New York 60
Helsinki 54
The Dalles 51
Beijing 44
Santa Clara 42
Council Bluffs 41
Ho Chi Minh City 38
Hefei 37
Houston 37
Dallas 32
Lauterbourg 32
Hanoi 28
Medford 28
Tokyo 27
Woodbridge 27
Chicago 26
Frankfurt am Main 25
Seattle 25
Milan 22
Wilmington 22
Buffalo 21
São Paulo 17
Des Moines 15
Lawrence 15
Ludwigshafen am Rhein 15
Princeton 15
San Diego 14
Nuremberg 13
Orem 13
Altamura 12
Dublin 12
London 12
Atlanta 11
Warsaw 11
Denver 10
Johannesburg 10
Lappeenranta 10
Seoul 10
Ann Arbor 9
Bexley 9
Bremen 9
Kitzingen 9
Montreal 9
Toronto 9
Stockholm 8
Boston 7
Brooklyn 7
Cambridge 7
Falkenstein 7
Manchester 7
Phoenix 7
Pune 7
Central 6
Guangzhou 6
Mumbai 6
Nairobi 6
Poplar 6
Redondo Beach 6
Rio de Janeiro 6
Tappahannock 6
Vienna 6
Baku 5
Brasília 5
Chennai 5
Dhaka 5
Montevideo 5
Munich 5
Padova 5
Quảng Ngãi 5
San Francisco 5
Volla 5
Amsterdam 4
Baghdad 4
Belo Horizonte 4
Brussels 4
Cagliari 4
City of London 4
Kilburn 4
Mexico City 4
Quito 4
Roubaix 4
Salt Lake City 4
Santa Catarina 4
Tashkent 4
Tianjin 4
Turin 4
Abidjan 3
Ankara 3
Bauru 3
Totale 2.787
Nome #
BRCA1/2 pathogenic variants in triple-negative versus luminal-like breast cancers: genotype–phenotype correlation in a cohort of 531 patients 225
A “lymphocyte microrna signature” as predictive biomarker of immunotherapy response and plasma pd-1/pd-l1 expression levels in patients with metastatic renal cell carcinoma: Pointing towards epigenetic reprogramming 217
Baseline plasma levels of soluble PD-1, PD-L1, and BTN3A1 predict response to nivolumab treatment in patients with metastatic renal cell carcinoma: a step toward a biomarker for therapeutic decisions 214
Detection of Germline Mutations in a Cohort of 139 Patients with Bilateral Breast Cancer by Multi-Gene Panel Testing: Impact of Pathogenic Variants in Other Genes beyond BRCA1/2 210
BRCA1/2 variants of unknown significance in hereditary breast and ovarian cancer (HBOC) syndrome: Looking for the hidden meaning 187
Exploring the Dynamic Crosstalk between the Immune System and Genetics in Gastrointestinal Stromal Tumors 175
Not all KIT 557/558 codons mutations have the same prognostic influence on recurrence-free survival: breaking the exon 11 mutations in gastrointestinal stromal tumors (GISTs) 175
Theranostic biomarkers and PARP-inhibitors effectiveness in patients with non-BRCA associated homologous recombination deficient tumors: Still looking through a dirty glass window? 175
MUTYH-associated tumor syndrome: The other face of MAP 171
POLE, POLD1, and NTHL1: the last but not the least hereditary cancer-predisposing genes 165
KIT/PDGFRA Variant Allele Frequency as Prognostic Factor in Gastrointestinal Stromal Tumors (GISTs): Results From a Multi-Institutional Cohort Study 161
Impact of deleterious variants in other genes beyond BRCA1/2 detected in breast/ovarian and pancreatic cancer patients by NGS-based multi-gene panel testing: looking over the hedge 160
Prognostic role of soluble PD-1 and BTN2A1 in overweight melanoma patients treated with nivolumab or pembrolizumab: finding the missing links in the symbiotic immune-metabolic interplay 156
Challenges and advances for the treatment of renal cancer patients with brain metastases: From immunological background to upcoming clinical evidence on immune-checkpoint inhibitors 154
Low plasma PD-L1 levels, early tumor onset and absence of peritoneal carcinomatosis improve prognosis of women with advanced high-grade serous ovarian cancer 153
Potential agnostic role of BRCA alterations in patients with several solid tumors: One for all, all for one? 153
Can the tumor-agnostic evaluation of MSI/MMR status be the common denominator for the immunotherapy treatment of patients with several solid tumors? 145
Prevalence and Spectrum of Germline BRCA1 and BRCA2 Variants of Uncertain Significance in Breast/Ovarian Cancer: Mysterious Signals From the Genome 142
Body mass index and baseline platelet count as predictive factors in Merkel cell carcinoma patients treated with avelumab 140
Impact of Different Selection Approaches for Identifying Lynch Syndrome-Related Colorectal Cancer Patients: Unity Is Strength 137
BRCA functional domains associated with high risk of multiple primary tumors and domain-related sensitivity to olaparib: the Prometheus Study 135
Can circulating PD-1, PD-L1, BTN3A1, pan-BTN3As, BTN2A1 and BTLA levels enhance prognostic power of CA125 in patients with advanced high-grade serous ovarian cancer? 130
BRCA-associated hereditary male cancers: can gender affect the prevalence and spectrum of germline pathogenic variants? 130
Prognostic role of plasma pd‐1, pd‐l1, pan‐btn3as and btn3a1 in patients affected by metastatic gastrointestinal stromal tumors: Can immune checkpoints act as a sentinel for short‐term survival? 129
Anthracycline-related cardiotoxicity in patients with breast cancer harboring mutational signature of homologous recombination deficiency (HRD) 126
Clinical relevance of exosome-derived microRNAs in Ovarian Cancer: Looking for new tumor biological fingerprints 123
The intersection of homologous recombination (HR) and mismatch repair (MMR) pathways in DNA repair-defective tumors 120
Scientific Communication and oncology – "The bridge between knowledge and patients" 117
Prognostic and Predictive Role of Tumor-Infiltrating Lymphocytes (TILs) in Ovarian Cancer 111
Liquid biopsy and immunotherapy: is all that glitter gold? 107
POTENTIAL APPLICATIONS OF LIQUID BIOPSY IN IMMUNOTHERAPY: ROLE OF EXOSOMES, MICRORNAS AND PLASMA EXPRESSION LEVELS OF IMMUNE CHECKPOINTS IN PATIENTS WITH SOLID TUMORS 92
Role of the HIPPO pathway as potential key player in the cross talk between oncology and cardiology 91
POLE-mutated endometrial cancer: new perspectives on the horizon? 75
Totale 4.901
Categoria #
all - tutte 18.942
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 18.942


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202132 0 0 0 0 0 0 0 0 0 0 5 27
2021/2022202 13 13 3 0 26 7 8 15 14 24 39 40
2022/2023363 28 64 10 48 40 41 16 37 32 4 27 16
2023/2024420 14 31 19 38 22 77 51 53 4 39 18 54
2024/20251.054 7 79 81 41 50 61 175 96 44 177 110 133
2025/20262.691 278 101 194 268 317 449 403 262 188 164 67 0
Totale 4.901